Press releases

Aglaris Appoints New CEO to Drive Commercialisation of Ground-breaking Cell-based Therapy Manufacturing System

09/10/2018

Aglaris Appoints New CEO to Drive Commercialisation of Ground-breaking Cell-based Therapy Manufacturing System

Madrid and London – 8 October 2018, Aglaris Ltd. today announced the appointment of Steven Docksey to the role of CEO of the Anglo-Spanish cell therapy equipment manufacturer, effective immediately. Aglaris is creating transformative technologies...

Nuubo Receives U.S. FDA 510(k) Clearance for the Nuubo System

07/09/2018

Nuubo Receives U.S. FDA 510(k) Clearance for the Nuubo System

MADRID, September 7.– Spanish medical device innovator Nuubo (https://www.nuubo.com) today announced it has received United States Food and Drug Administration (FDA) 510(k) clearance to market its Nuubo System, a disruptive wireless, textile-based...

Atlas Molecular Pharma Receives European Medicines Agency (EMA) Orphan Designation for Congenital Erythropoietic Porphyria

10/01/2018

Atlas Molecular Pharma Receives European Medicines Agency (EMA) Orphan Designation for Congenital Erythropoietic Porphyria

January 10, 2018 DERIO, Spain.- Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) by the Centre for Co-operative Research in Biosciences (CIC bioGUNE) and the Venture Capital Firm CRB Inverbio, today announced...

OWL Metabolomics participates in one of the most innovative European research projects to develop the best diagnostic tool for liver diseases.

24/11/2017

OWL Metabolomics participates in one of the most innovative European research projects to develop the best diagnostic tool for liver diseases.

The Target of the Litmus Project focused to optimize and validate diagnostic tools for an early evaluation of patients with Non-Alcoholic Fatty Liver (NAFL) and to identify those with higher risk of severe inflammation and cirrhosiround-breaking €34...

IDEN BIOTECHNOLOGY PARTNERS WITH J.R. SIMPLOT COMPANY ON GENE DISCOVERY FOR POTATO ADVANCEMENTS

14/11/2017

IDEN BIOTECHNOLOGY PARTNERS WITH J.R. SIMPLOT COMPANY ON GENE DISCOVERY FOR POTATO ADVANCEMENTS

NAVARRA, SPAIN - Iden Biotechnology and the J.R. Simplot Company, companies involved in agricultural solutions through biotechnology, recently entered into an agreement to explore the potential for nutritional enrichment in the potato. As part of the...

TIERRA AGROTECH AND IDEN BIOTECHNOLOGY CREATE JOINT VENTURE “TIDAS AGROTECH” FOR BIOLOGICALS COMMERCIALIZATION IN INDIA

18/10/2017

TIERRA AGROTECH AND IDEN BIOTECHNOLOGY CREATE JOINT VENTURE “TIDAS AGROTECH” FOR BIOLOGICALS COMMERCIALIZATION IN INDIA

TIERRA AGROTECH and IDEN BIOTECHNOLOGY, companies operating on the seeds and agriculture solutions sector, have recently created the Joint Venture TIDAS AGROTECH PRIVATE LIMITED for the development and commercialization of biological solutions for farmers...

ProSciento and OWL Metabolomics Form Strategic Collaboration Focused on Accelerating NAFLD/NASH Clinical Trial Recruitment

12/06/2017

ProSciento and OWL Metabolomics Form Strategic Collaboration Focused on Accelerating NAFLD/NASH Clinical Trial Recruitment

Companies enter into an exclusive, multi-year partnership to employ non-invasive, lipidomics-based diagnostic testing to establish a database enriched for subjects with NAFLD/NASH SAN DIEGO and DERIO, SPAIN, June 7, 2017 /PRNewswire/ – ProSciento,...

OWL Metabolomics to Open U.S. Headquarters in Virginia Beach

05/05/2017

OWL Metabolomics to Open U.S. Headquarters in Virginia Beach

Company will Co-Locate with Sanyal Biotechnology in VABeachBio Accelerator Tuesday, April 25, 2017 ​One Way Liver S.L. (OWL Metabolomics) announced plans to open their U.S. Headquarters in the VABeachBio Accelerator in Virginia Beach as part of their...

Metabolomics-based testing shown to improve the diagnosis and treatment of non-alcoholic fatty liver disease (NAFLD)

27/02/2017

Metabolomics-based testing shown to improve the diagnosis and treatment of non-alcoholic fatty liver disease (NAFLD)

CIC bioGUNE and OWL Metabolomics identify two subtypes of NAFLD The study, performed with 535 biopsied proved NAFLD patients and analyzing more than 400 lipids, has been published in the journal Gastroenterology. The metabolomics analysis, performed...

Oncovision completes the sale of the preclinical PET imaging business to Bruker

24/11/2016

Oncovision completes the sale of the preclinical PET imaging business to Bruker

Value-creating divestment supports OncoVision focus on the clinical business while Bruker strengthens its leadership in preclinical imaging Valencia, Spain – November 22, 2016 –  Oncovision a leading manufacturer of medical imaging...

Iden Biotechnology welcomes Francisco J.M. Mojica, CRISPR-Cas renowed expert to its advisory panel

24/10/2016

Iden Biotechnology welcomes Francisco J.M. Mojica, CRISPR-Cas renowed expert to its advisory panel

Iden Biotechnology announces the incorporation of Dr Francisco J.M. Mojica, world class expert in CRISPR-Cas technology, to its Advisory Panel, bringing exceptional experience and knowledge applicable to new plant breeding techniques. CRISPR-Cas, gives...

 

23/05/2016

CRB Inverbio is participating in the 15th National Life Sciences & Technology Week in Tel-Aviv

This year and for the first time, CRB Inverbio is participating in the 15th IATI Biomed 2016 Conference and Exhibition, to be held May 24-26 in Tel-Aviv, Israel IATI Biomed Israel is a conference gathering each year more than 6,000 visitors, active...

Sanyal Biotechnology LLC Announces Strategic Partnership with OWL Metabolomics, S.L.

21/04/2016

Sanyal Biotechnology LLC Announces Strategic Partnership with OWL Metabolomics, S.L.

April 16, 2016 – Richmond, Virginia and Barcelona, Spain:  Sanyal Biotechnology LLC and One Way Liver S.L. (OWL Metabolomics) have today initiated a strategic partnership to provide increased value and additional R&D services to basic...

OWL Metabolomics will present new data regarding innovations in NASH and NAFLD diagnosis in the settings of clinical practice and companion diagnostic testing (CDx) for NASH trials at the forthcoming 2016 EASL/ILC Congress.

07/04/2016

OWL Metabolomics will present new data regarding innovations in NASH and NAFLD diagnosis in the settings of clinical practice and companion diagnostic testing (CDx) for NASH trials at the forthcoming 2016 EASL/ILC Congress.

OWL Metabolomics will present new data regarding innovations in NASH and NAFLD diagnosis in the settings of clinical practice and companion diagnostic testing (CDx) for NASH trials at the forthcoming 2016 EASL/ILC Congress. Bilbao (Spain), Press Release,...

Iden Biotechnology S.L. announces a new collaboration to develop GM wheat resistance to low temperature with Bioceres S.A., based in Rosario, Argentina

16/03/2016

Iden Biotechnology S.L. announces a new collaboration to develop GM wheat resistance to low temperature with Bioceres S.A., based in Rosario, Argentina

IDEN Biotechnology S.L., today announced that has signed an agreement with Bioceres S.A., an agricultural biotechnology company[1], for the co-development and commercialization of specific wheat genetic traits. The agreement comprises a technology developed...

OWL Metabolomics announces the appointment of an international team of leading experts to its newly formed Scientific Advisory Board

01/03/2016

OWL Metabolomics announces the appointment of an international team of leading experts to its newly formed Scientific Advisory Board

OWL Metabolomics announces the appointment of an international team of leading experts to its newly formed Scientific Advisory Board Derio, Spain - (Press Release) March 1, 2016 -- OWL Metabolomics, an emerging leader in the development of innovative...

Spanish Venture Capital Fund CRB Bio II invests €2M in Aglaris Ltd.

01/03/2016

Spanish Venture Capital Fund CRB Bio II invests €2M in Aglaris Ltd.

Aglaris is developing an automated cell culture bioreactor for the mass production of human stem cells. The Company was founded in 2012 and currently operates from its two locations in Madrid and London. Financing will advance the development of...

 

10/11/2015

Immuron Commences NASH Companion Diagnostic Collaboration with OWL Metabolomics

Monday 9th November 2015 – Melbourne, Australia: Immuron Limited and One Way Liver S.L. (OWL Metabolomics), a leader in the field of metabolomics and liver diseases diagnostics, have  signed a collaboration agreement to evaluate and validate...

 

11/09/2015

Iden Biotechnology Key Patents Granted in China, USA and Europe

Iden Biotechnology Key Patents Granted in China, USA and Europe September 10, 2015                    -- Patents providing protection on Crop Improvement...

 

08/07/2015

Galmed Pharmaceuticals Unfolds the Development fo Aramchol(TM) Non-Invasive Companion Diagnostic Program

The company announced today that it has entered into a Research, Option and License Agreement and a Share Purchase Agreement with OWL.

 

24/02/2015

Iden Biotechnology completes Eur 4 Million Capital Increase with strategic investors CRB Inverbío and Sodena

The capital increase will allow the Company to extend its facilities and staff in Navarra

 

01/10/2014

The first non-invasive test to diagnose fatty liver disease is awarded two patents in the US

The diagnostic test, which correctly categorises the disease in 94% of patients, is
already being marketed as Owl Liver by the Basque company Owl.

 

 

17/09/2014

nLife Therapeutics receives USD 350,000 from The Michael J. Fox Foundation for Parkinson’s Research

The funding will help characterize the mechanism of action of nLife’s lead compound NLF-PD-1233 in a Parkinson disease model and find a proper dose to engage clinical development

 

09/04/2014

Oncovision Expands into Cambridge

Oncovision, an innovative medical imaging technology company from Valencia, Spain, announced the opening of its U.S. subsidiary,Oncovision, Inc., located in Boston. Oncovision plans to hire 4 to 5 employees in Boston by the end of 2014, and to open a...

 

10/03/2014

Ferrer acquire an 18% stake in Spanish biotech Venter Pharma

The transaction, which includes the acquisition of shares from existing shareholders plus newly issued shares, is worth 3.5 million euros ($5M). 

 

11/12/2013

Venter Pharma and NovaMedica sign agreement to commercialize intolerance test in Russia

NovaMedica plans to conduct a clinical development program on LacTEST® and to apply for regulatory approval of the product in Russia. Sales are projected to begin in 2015. Venter Pharma retains the rights to commercialize the product in countries...

 

10/09/2013

Green Molecular S.L. Licenses Exclusive Worlswide Patent Rights for Pterostilbene Relating to Skin Care to ChromaDex®

As part of the same agreement the Company also grants Right of First Refusal for Combined Use os Pterostilbene and Quercetin for the Prevention and/or Treatment of Skin Cancer 

 

 

10/01/2012

TCD Pharma Announces €1.5M Equity Investment by ADE Capital Sodical SCR

The funds will enable the Company to continue the development of TCD-717, its leading product currently in a Phase I clinical trial for the treatment of cancer, as well as expanding its pipeline.

 

25/02/2011

TCD Announces First Patient Treated in its TCD-717 Phase I Trial

Madrid, Spain 28th of February, 2011 -- Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid...

 

30/09/2010

CRB bio II Fund Launched to Invest in Early Stage Biotech in Spain

CRB Bio II, a new investment fund focused in early stage life science companies. The Fund will be managed by a new Venture Capital Firm (CRB Inverbío) created by the founding partners of Cross Road Biotech, a Spanish venture capital company with wide...

 

01/09/2010

Blood test developed for non-alcoholic fatty liver disease diagnosis

The metabolomics-based blood test developed by OWL Genomics and CIC bioGUNE will contribute to the early diagnosis of NASH, which affects up to 24% of the US and European population.

RSS de esta página